脂蛋白(a)水平对糖尿病患者心脏病理的影响:一项心脏CT研究
前瞻性纳入207例糖尿病患者,按脂蛋白(a) cutoff 30 mg/dL分为升高组与正常组,行CT血管成像、负荷CT心肌灌注成像及晚期碘增强。脂蛋白(a)升高与更明显的动脉粥样硬化斑块负荷及高风险斑块独立相关,但与冠周脂肪密度、负荷心肌血流量及细胞外容积无显著差异。
要点
- 糖尿病伴脂蛋白(a)升高者动脉粥样硬化斑块负荷更重,高风险斑块发生率更高。
- 脂蛋白(a)升高是高风险斑块的独立相关因素(OR 2.608,95%CI 1.254-5.423)。
- 脂蛋白(a)升高与冠周脂肪密度、负荷心肌血流量及细胞外容积无显著差异。
核心结论
- 脂蛋白(a)升高与糖尿病患者更广泛的冠状动脉粥样硬化和高风险斑块发生相关,但与血管周围炎症、心肌灌注减低及间质纤维化无关。
研究设计与样本
- 前瞻性研究,纳入20个月内接受CT血管成像、负荷CT心肌灌注成像及晚期碘增强的糖尿病患者207例(平均年龄59.1±12.0岁,男性111例),按脂蛋白(a) cutoff 30 mg/dL分为升高组与正常组。
关键影像表现/征象
- 脂蛋白(a)升高组斑块体积百分比为2.55%(1.01-9.01%),正常组为1.30%(0-4.95%),p=0.010。
- 脂蛋白(a)升高组正性重构发生率为75.6%,正常组为54.8%,p=0.015。
- 脂蛋白(a)升高组点状钙化发生率为26.8%,正常组为9.6%,p=0.003。
- 脂蛋白(a)升高组高风险斑块发生率为51.2%,正常组为30.1%,p=0.011。
诊断标准与关键数值
- 脂蛋白(a) cutoff 水平为30 mg/dL,据此分为升高组与正常组。
- 多因素分析显示,调整所有临床特征后,脂蛋白(a)升高是与高风险斑块独立相关的参数(OR=2.608,95%CI 1.254-5.423,p=0.010)。
- 冠周脂肪密度、负荷心肌血流量及细胞外容积在两组间无显著差异。
临床应用与阅片要点
- 作者建议糖尿病患者应使用CCTA筛查脂蛋白(a)升高,以全面评估动脉粥样硬化特征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: We aimed to explore the imaging profile of coronary atherosclerosis, perivascular inflammation, myocardial perfusion, and interstitial fibrosis in diabetes stratified by lipoprotein(a) [Lp(a)] levels.
METHODS: In this prospective study, we enrolled diabetic patients who had undergone computed tomography (CT) angiography, stress CT-myocardial perfusion imaging, and late iodine enhancement in 20 months. Then, we categorized them into elevated and normal groups based on an Lp(a) cutoff level of 30 mg/dL. All imaging data, including coronary atherosclerosis parameters, pericoronary adipose tissue (PCAT) density, stress myocardial blood flow (MBF), and extracellular volume (ECV), were collected for further analysis.
RESULTS: In total, 207 participants (mean age: 59.1 ± 12.0 years, 111 males) were included in this study. Patients with elevated Lp(a) level had more pronounced percent atheroma volume (2.55% (1.01-9.01%) versus 1.30% (0-4.95%), p = 0.010), and demonstrated a higher incidence of positive remodeling, spotty calcification, and high-risk plaque (HRP) than those with normal Lp(a) levels (75.6% versus 54.8%, p = 0.015; 26.8% versus 9.6%, p = 0.003; 51.2% versus 30.1%, p = 0.011, respectively). Results of the multivariate analysis revealed that after adjusting for all clinical characteristics, elevated Lp(a) levels were an independent parameter associated with HRP (odds ratio = 2.608; 95% confidence interval: 1.254-5.423, p = 0.010). However, no significant difference was found between the two groups in terms of PCAT density, stress MBF, and ECV.
CONCLUSIONS: Elevated Lp(a) levels are associated with extensive coronary atherosclerosis and HRP development. However, they are not related to perivascular inflammation, decreased myocardial perfusion, and interstitial fibrosis in diabetes.
CLINICAL RELEVANCE STATEMENT: Elevated lipoprotein(a) levels are associated with extensive coronary atherosclerosis and a high incidence of HRPs. However, they are not related to perivascular inflammation, decreased myocardial perfusion, and interstitial fibrosis in diabetes.
KEY POINTS: Diabetes is a known risk factor that accelerates cardiovascular disease progression. Diabetics with elevated lipoprotein(a) (Lp(a)) levels had a higher percent atheroma volume and positive remodeling, spotty calcification, and HRPs. Patients with diabetes should be screened for elevated Lp(a) using CCTA for comprehensive evaluation of atherosclerotic characteristics.
引用
- Yuan J, Ding X, Yang W, et al. The impact of lipoprotein(a) level on cardiac pathologies in diabetes: a cardiac CT study. Eur Radiol. 2024. PMID: 38995383. doi:10.1007/s00330-024-10903-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。